Pancreatic Cancer Treatment Protocols Adjusted After Surgery
Following liver surgery for advanced cancer, doctors shifted chemotherapy plans due to treatment resistance.
Updated on Sept. 23, 2026 in Cancer
Former Senator Ben Sasse underwent surgery at MD Anderson Cancer Center in Houston last week to remove a significant amount of cancer. The procedure followed reports that his Stage 4 pancreatic cancer had developed resistance to previous treatment protocols.
Why it matters
When a tumor becomes resistant to standard therapies, medical teams often shift to aggressive chemotherapy regimens to target mutations. This case highlights how clinicians adapt care plans based on ongoing monitoring of treatment response.
This clinical development follows the patient's enrollment in a 2026 clinical trial for daraxonrasib, which received FDA accelerated approval in August 2026. The shift to aggressive chemotherapy was prompted by tumor mutation tests.
The players
Ben Sasse
A 54-year-old former U.S. Senator for Nebraska and former president of the University of Florida currently undergoing cancer treatment.
MD Anderson Cancer Center
A Houston-based medical institution specializing in cancer research and advanced patient care.
The details
Surgeons performed a procedure to clear out cancer from the liver after testing indicated the disease had advanced. The medical team responded by pivoting to a new chemotherapy protocol designed to address specific genetic mutations found in the resistant tumors. This aggressive approach is standard when initial therapies, including clinical trial drugs, no longer effectively contain tumor growth.
Timeline
December 2025: Sasse revealed his Stage 4 pancreatic cancer diagnosis.
January 2026: Sasse entered a clinical trial for the drug daraxonrasib.
Late August 2026: The FDA granted daraxonrasib accelerated approval.
September 2026: Sasse underwent liver surgery at MD Anderson Cancer Center.
Health Landscape
The clinical use of daraxonrasib reflects the evolving landscape of targeted oncology therapies made available through the FDA's accelerated approval pathway. This approach aims to bring new treatments to patients with rare or advanced mutations before traditional long-term survival data is finalized.
For those managing advanced cancer, this case illustrates why regular re-testing for tumor mutations is a standard part of navigating treatment resistance. It is worth discussing with your oncology team how periodic testing might inform adjustments to your own therapeutic regimen.
The takeaway
Advanced cancer care often requires rapid adjustments when tumors stop responding to initial protocols. Patients and their families should work closely with oncologists to understand how new biopsy results or genetic testing may necessitate a change in treatment strategy.
What happens next
Ben Sasse is scheduled to serve as the keynote speaker at the Governor's Summit in Kearney, Nebraska, next week.
Further reading
For more on evolving standards of care, visit our Cancer section.
